Skip Navigation

A Feasibility and Randomized Phase II/III Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma

Brief Summary

Type:
Sarcomas

Study Type:
Treatment

Phase:
II/III

ClinicalTrials.gov Identifier:
NCT05691478

Study #:
CMH - AOST2032

Start Date:
Aug 25, 2023

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT05691478

View Complete Trial Details & Eligibility at ClinicalTrials.gov